HS-10370

DRUG4 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorAdvanced Solid TumorsCarcinoma, Non-Small-Cell LungColorectal CancerNon-Small Cell Lung Cancer

Phase 1

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

RecruitingNCT05367778

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2022-06-03End: 2026-04-30Target: 176Updated: 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Not yet recruitingNCT06594874

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumors, Non-Small Cell Lung Cancer

Start: 2024-10-31End: 2027-01-01Target: 350Updated: 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Not yet recruitingNCT06963502

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer

Start: 2025-05-30End: 2030-04-30Target: 762Updated: 2025-05-09

Phase 3

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Not yet recruitingNCT07822542

Jiangsu Hansoh Pharmaceutical Co., Ltd.Carcinoma, Non-Small-Cell Lung

Start: 2026-10-31End: 2031-12-31Target: 448Updated: 2026-09-16

Related Papers

Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study

Cancer Research2025-04-253 citations

Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Cancer Research2024-04-055 citations